Valutazione di efficacia di un antiangiogenetico (Bevacizumab)

[11] Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K. ErbB2 overexpression
on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
Cancer Res. 2001;61:1890-5.
[12] van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton
MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene
expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-6.
[13] van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts
C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H,
Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med. 2002;347:1999-2009.
[14] Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, Brakenhoff R, Pantel K. Molecular
signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res.
2003;63:5679-84.
[15] Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van
Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant
metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671-9.
[16] Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid
tumors. Nat Genet. 2003;33:49-54.
[17] Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J,
Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent
disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl
Acad Sci U S A. 2003;100:7737-42.
[18] Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmuller G.
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002;360:683-
9.
[19] Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic
tumors. Cancer Cell. 2003;4:4-6.
[20] Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M,
Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL.
Maria Pittalis
Valutazione di efficacia di un antiangiogenetico (Bevacizumab) associata a chemioterapia in pazienti con carcinoma
della mammella metastatico
Tesi di dottorato in scienze Biomediche-Epidemiologia molecolare dei tumori
Università degli Studi di Sassari
81